<DOC>
	<DOC>NCT02173262</DOC>
	<brief_summary>The Integrated Consent Model is being increasingly used internationally to improve patient care. In this feasibility study we will explore whether the model is feasible in practice; and whether it can be used to increase the number of physicians and patients who take part in clinical trials, and address the critical issue around the optimal febrile neutropenia prevention by randomizing eligible patients to either G-CSF or ciprofloxacin.</brief_summary>
	<brief_title>REaCT Integrated Consent Model to Compare Two Standard of Care Regimens</brief_title>
	<detailed_description />
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>Histologically confirmed primary breast cancer Planned TC chemotherapy ≥19 years of age Able to provide verbal consent Willing to complete a survey • Contraindication to either Ciprofloxacin or GCSF</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Breast</keyword>
</DOC>